Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 1.00 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.53 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.52 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.50 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23666164 | 1.00 | KIF11 (1.00) | KIF11CYP2A6CYP3A4ALDH1A1CYP1A2 | |
| SCHEMBL2250286 | 0.91 | KIF11 (0.83) | KIF11CYP2A6CYP3A4ALDH1A1CYP1A2 | |
| SCHEMBL24977263 | 0.90 | KIF11 (0.81) | KIF11CYP2A6CYP3A4ALDH1A1CYP1A2 | |
| SCHEMBL20371363 | 0.88 | KIF11 (0.78) | KIF11CYP2A6CYP3A4ALDH1A1CYP1A2 | |
| SCHEMBL25390854 | 0.88 | KIF11 (0.78) | KIF11CYP2A6CYP3A4ALDH1A1CYP1A2 | |
| SCHEMBL13726280 | 0.86 | KIF11 (0.73) | KIF11CYP2A6CYP3A4ALDH1A1CYP1A2 | |
| SCHEMBL19735248 | 0.85 | KIF11 (0.74) | KIF11CYP2A6CYP3A4ALDH1A1CYP1A2 | |
| SCHEMBL20805743 | 0.85 | KIF11 (0.74) | KIF11CYP2A6CYP3A4ALDH1A1CYP1A2 | |
| SCHEMBL4502483 | 0.85 | KIF11 (0.73) | KIF11CYP2A6CYP3A4ALDH1A1CYP1A2 | |
| SCHEMBL17680285 | 0.85 | KIF11 (0.73) | KIF11CYP2A6CYP3A4ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807641-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230312499-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2023-10-05 | — | — | US | disclosed |
| US-20230312499-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2023-10-05 | — | — | US | disclosed |
| US-20230301184-A1 | ORGANIC COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE AND ELECTRONIC APPARATUS THEREOF | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-09-21 | — | — | US | disclosed |
| US-11760817-B2 | Mass polymerizable polycycloolefin compositions containing soluble photoacid generators | PROMERUS, LLC (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230250090-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES INC (US) | 2023-08-10 | — | — | US | disclosed |
| US-11723268-B2 | Organic light-emitting element | LG CHEM, LTD. | 2023-08-08 | — | — | US | disclosed |
| US-11723268-B2 | Organic light-emitting element | LG CHEM, LTD. | 2023-08-08 | — | — | US | disclosed |
| US-11718583-B2 | Nitrogen-containing compound, electronic component using same and electronic device | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-08-08 | — | — | US | disclosed |
| US-11700768-B2 | Compound and organic light emitting device comprising the same | LG CHEM, LTD. (KR) | 2023-07-11 | — | — | US | disclosed |
| US-7557110-B2 | MAPKAP-K2; inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth; 5-[(trans-4-aminocyclohexyl)amino]-3-fluoro-6-methyl(pyrazolo[1,5-a]pyri- midin-7-yl)}(4-iodophenyl)amine | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20090054472-A1 | Pyrazolopyrimidine Derivatives or Pharmaceutically Acceptable Salts Thereof | TEIJIN PHARMA LIMITED (JP) | 2009-02-26 | — | — | US | disclosed |
| US-20090054472-A1 | Pyrazolopyrimidine Derivatives or Pharmaceutically Acceptable Salts Thereof | TEIJIN PHARMA LIMITED (JP) | 2009-02-26 | — | — | US | disclosed |
| US-7473694-B2 | Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED (JP) | 2009-01-06 | — | — | US | disclosed |
| US-7361654-B2 | Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB CO. (US) | 2008-04-22 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| US-20070173519-A1 | Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED | 2007-07-26 | — | — | US | disclosed |
| US-20070111994-A1 | Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-05-17 | — | — | US | disclosed |
| US-20070111994-A1 | Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054472-A1 | Pyrazolopyrimidine Derivatives or Pharmaceutically Acceptable Salts Thereof | MAPKAPK2, MAPKAPK5, MAPKAPK3 | KIF11 1496/4885CYP2A6 3496/4885CYP3A4 4450/4885 |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | KIF11 3394/4885CYP2A6 4656/4885CYP3A4 4706/4885 |
| US-20230250090-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | KIF11 3370/4885CYP2A6 3460/4885CYP3A4 4184/4885 |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | HDAC1, HDAC11, HDAC5 | KIF11 1491/4885CYP2A6 4390/4885CYP3A4 4595/4885 |
| US-20070173519-A1 | Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof | MAPKAPK2, MAPKAPK5, MAPKAPK3 | KIF11 1496/4885CYP2A6 3496/4885CYP3A4 4450/4885 |
| US-11700768-B2 | Compound and organic light emitting device comprising the same | ARL1, ARRB1, CRY1 | KIF11 4237/4885CYP2A6 1791/4885CYP3A4 769/4885 |
| US-11718583-B2 | Nitrogen-containing compound, electronic component using same and electronic device | EXOC1, NOS1, EXOSC10 | KIF11 3575/4885CYP2A6 4002/4885CYP3A4 2434/4885 |
| US-20230312499-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, ABHD16A, RABL6 | KIF11 1377/4885CYP2A6 218/4885CYP3A4 3727/4885 |
| US-20070111994-A1 | Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties | BAD, GABRA5, GABRB1 | KIF11 4574/4885CYP2A6 1415/4885CYP3A4 800/4885 |
| US-20230301184-A1 | ORGANIC COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE AND ELECTRONIC APPARATUS THEREOF | OCIAD1, OCIAD2, OSTC | KIF11 2584/4885CYP2A6 812/4885CYP3A4 75/4885 |
| US-11760817-B2 | Mass polymerizable polycycloolefin compositions containing soluble photoacid generators | PPOX, VCL, PFN1 | KIF11 1890/4885CYP2A6 4320/4885CYP3A4 3186/4885 |
| US-11723268-B2 | Organic light-emitting element | CRY2, NR2E3, CRY1 | KIF11 3531/4885CYP2A6 524/4885CYP3A4 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.